Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma

TORONTO, March 20, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), an immuno-oncology company developing innovative therapies for the treatment of cancer, today...
March 09, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Annual 2017 Financial and Operating Results

Presented evidence of clinical activity and good tolerability from both TTI-621 trials at ASHReceived FDA clearance to proceed with second clinical CD47 program, TTI-622Cash and marketable securities...
January 17, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
December 11, 2017 08:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Provides Update on its TTI-621 Program at the American Society of Hematology 59th Annual Meeting

TORONTO, ONTARIO--(Marketwired - Dec. 11, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
December 01, 2017 22:21 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Closing of Private Placement

TORONTO, ONTARIO--(Marketwired - Dec. 1, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
November 20, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting

TORONTO, ONTARIO--(Marketwired - Nov. 20, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
November 15, 2017 09:15 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Private Placement

TORONTO, ONTARIO--(Marketwired - Nov. 15, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
November 13, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting

TORONTO, ONTARIO--(Marketwired - Nov. 13, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
November 10, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results

TORONTO, ONTARIO--(Marketwired - Nov. 10, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
November 06, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Present at Upcoming Scientific Conferences

TORONTO, ONTARIO--(Marketwired - Nov. 6, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the...